New cancer drug RPH-002 tested against standard therapy in head and neck cancer trial
Disease control
Completed
This study tested a new drug called RPH-002 against the standard drug Erbitux in 118 people with advanced head and neck cancer that could not be removed by surgery. The goal was to compare how the drugs move through the body and check for side effects when given with chemotherapy…
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated May 01, 2026 15:59 UTC